VRDN - Viridian Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.88
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$42.89
DETAILS
HIGH:
$50.00
LOW:
$34.00
MEDIAN:
$45.00
CONSENSUS:
$42.89
UPSIDE:
45.88%
Market Cap:
2.39B
Volume:
1,484,544
Avg Volume:
1,507,670
52 Week Range:
9.9-34.29
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.98
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
143
IPO Date:
2014-06-18
EPS (TTM):
-3.98
P/E Ratio:
-4.82
Revenue (TTM):
302,000
Total Assets:
742.40M
Total Debt:
21.09M
Cash & Equiv:
99.59M
Rev Growth (5Y):
-41.6%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-38.4%
Debt/Equity:
0.03
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.34 | $-0.82 | +58.5% | $70.6M | $15.8M | +346.8% |
| 2025-05-06 | $-0.87 | $-0.95 | +8.4% | $72000 | $44080 | +63.3% |
| 2025-02-27 | $-0.81 | $-1.05 | +22.9% | $72000 | $50000 | +44.0% |
| 2024-11-12 | $-1.15 | $-1.06 | -8.5% | $86000 | $50000 | +72.0% |
| 2024-08-08 | $-1.02 | $-0.89 | -14.6% | $72000 | $80000 | -10.0% |
| 2024-05-08 | $-0.79 | $-1.10 | +28.2% | $72000 | $70000 | +2.9% |
| 2024-02-27 | $-1.35 | $-1.00 | -35.0% | $72000 | $154182 | -53.3% |
| 2023-11-13 | $-1.09 | $-1.27 | +14.2% | $72000 | $160000 | -55.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 302,000 | 314,000 | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.34M | 2.54M | 4.32M | 4.32M |
| Net Income | (269.95M) | (237.73M) | (129.87M) | (79.41M) | (110.72M) | (41.87M) | (32.70M) | (26.51M) | (12.67M) | (11.33M) | (7.89M) | (2.16M) |
| EPS | -3.98 | -5.31 | -3.91 | -6.66 | -31.20 | -20.31 | -16.57 | -20.66 | -17.57 | -21.00 | -52.46 | -11.48 |
| Total Assets | 742.40M | 490.42M | 435.09M | 203.71M | 131.25M | 30.26M | 66.15M | 52.48M | 4.26M | 12.90M | 8.09M | 3.67M |
| Total Debt | 21.09M | 21.05M | 5.26M | 520,000 | 455,000 | 8.30M | 10.30M | 9.92M | 1.04M | 1.10M | 80,000 | 697,064 |
| Cash & Equivalents | 99.59M | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 3.34M | 10.83M | 5.12M | 209,348 |
| Operating Cash Flow | (232.32M) | (184.17M) | (93.84M) | (54.58M) | (29.78M) | (36.06M) | (26.84M) | (28.17M) | (7.23M) | (6.90M) | (2.21M) | (1.17M) |
| Free Cash Flow | (232.83M) | (185.07M) | (94.64M) | (54.92M) | (29.82M) | (36.14M) | (27.29M) | (28.41M) | (7.23M) | (7.02M) | (2.48M) | (1.17M) |
| FCF per Share | -3.43 | -4.14 | -2.95 | -4.61 | -8.38 | -17.30 | -13.83 | -22.15 | -10.03 | -13.02 | -16.48 | -6.23 |
| Book Value | 671.64M | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M | 51.34M | 38.51M | (326,000) | 10.41M | 5.99M | 2.03M |
| Cash & ST Investments | 717.58M | 477.37M | 424.55M | 196.97M | 127.64M | 26.84M | 62.48M | 47.44M | 3.34M | 10.83M | 5.12M | 209,348 |
| ROC Equity | -0.40 | -0.54 | -0.33 | -0.42 | -0.92 | -2.66 | -0.64 | -0.69 | N/A | -1.09 | -1.32 | -1.07 |